Conference Coverage

Tapering TNFi’s safe and much cheaper in RA

Publish date: December 1, 2014

 

AT THE ACR ANNUAL MEETING

References

Dr. van Herwaarden’s study was internally funded. Dr. Yoshida’s study was supported by a grant to Kameda Medical Center, Kamogawa City, Japan. Both physicians reported having no relevant disclosures.

Pages

Recommended Reading

VIDEO: BeST: Does a treat-to-target approach reduce RA mortality?
MDedge Rheumatology
Novel program improves RA care, cuts costs
MDedge Rheumatology
Treat-to-target approach cuts mortality risk in RA patients
MDedge Rheumatology
RA draft guidelines: Treat to target
MDedge Rheumatology
RA increases mortality, particularly for respiratory causes, in women
MDedge Rheumatology
VIDEO: Herpes zoster vaccination: Is it safe for rheumatology patients over age 30 on biologics?
MDedge Rheumatology
VIDEO: Lower heart failure risk seen in users of tumor necrosis factor inhibitors
MDedge Rheumatology
VIDEO: Collaborative clinic aims at heart of CVD prevention in rheumatic diseases
MDedge Rheumatology
VIDEO: DAGR may prove to be safer alternative to glucocorticoids
MDedge Rheumatology
Nonsteroidal ‘DAGR’ looks sharp against RA
MDedge Rheumatology